Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 17/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.86 |
| ▸ | MEN1 | O00255 | 4/20 | 0.86 |
| ▸ | NPC1 | O15118 | 4/20 | 0.86 |
| ▸ | RAB9A | P51151 | 4/20 | 0.86 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16554160 | 0.95 | SCD (1.00) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL4917823 | 0.93 | SCD (0.87) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL31243 | 0.92 | SCD (1.00) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL31065 | 0.91 | SCD (1.00) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL16554145 | 0.91 | SCD (0.88) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL16681363 | 0.91 | SCD (0.88) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL16553834 | 0.91 | SCD (1.00) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL12199259 | 0.90 | SCD (0.81) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL16562258 | 0.90 | SCD (0.81) | SCDKMT2AMEN1NPC1RAB9A | |
| SCHEMBL2484653 | 0.90 | SCD (0.81) | SCDKMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680431-A1 | BENZOTHIAZOLE AND THIAZOLE'5,5-B!PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2006-07-19 | — | — | EP | claimed |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | claimed |
| WO-2005037845-A1 | BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | claimed |
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789096-B2 | Methods and compositions for selective and targeted cancer therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-14 | — | — | US | disclosed |
| EP-3041470-A1 | METHODS AND COMPOSITIONS FOR SELECTIVE AND TARGETED CANCER THERAPY | Board Of Regents Of the University Of Texas System (US) | 2016-07-13 | — | — | EP | disclosed |
| US-9362510-B2 | Electroluminescent metal complexes with benzotriazoles | BASF SE (DE) | 2016-06-07 | — | — | US | disclosed |
| US-20100044688-A1 | ELECTROLUMINESCENT METAL COMPLEX | CIBA CORPORATION (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100044688-A1 | ELECTROLUMINESCENT METAL COMPLEX | CIBA CORPORATION (US) | 2010-02-25 | — | — | US | disclosed |
| WO-2008101842-A1 | ELECTROLUMINESCENT METAL COMPLEXES WITH BENZOTRIAZOLES | BASF SE (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008098851-A1 | ELECTROLUMINESCENT METAL COMPLEX | BASF SE (CH) | 2008-08-21 | — | — | WO | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | RIGEL PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005037845-A1 | BENZOTHIAZOLE AND THIAZOLE[5,5-B] PYRIDINE COMPOSITIONS AND THEIR USE AS UBIQUITIN LIGASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130974-A1 | Benzothiazole compositions and their use as ubiquitin ligase inhibitors | UBQLN1, UBE2T, NEDD4 | SCD 3790/4885KMT2A 1419/4885MEN1 3866/4885 |
| US-20100044688-A1 | ELECTROLUMINESCENT METAL COMPLEX | LDHA, LDHB, NRP1 | SCD 4566/4885KMT2A 3577/4885MEN1 1969/4885 |
| US-20080039629-A1 | Benzothniazole compositions and their use as ubiquition ligation inhibitors | UBQLN1, NEDD4, UCHL5 | SCD 3956/4885KMT2A 1591/4885MEN1 4194/4885 |
| US-20160200695-A1 | Methods and Compositions for Selective and Targeted Cancer Therapy | NCOA4, SREBF1, ACOX1 | SCD 4/4885KMT2A 1976/4885MEN1 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.